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Abstract
Introduction and hypothesis Interstitial cystitis/painful blad-
der syndrome (IC/PBS) is a chronic inflammatory condition
of the submucosal and muscular layers of the bladder. So far,
there is no effective and targeted treatment strategy for IC/
PBS. This study aimed to assess the efficacy and safety of
intravesical instillation treatment in IC/PBS patients.
Methods We searched various databases up to October 2015.
A network meta-analysis was performed to compare global
response assessment (GRA) for different treatment strategies,
including botulinum toxin A (BoNTA), bacillus Calmette–
Guerin (BCG), resiniferatoxin (RTX), lidocaine, chondroitin
sulfate (CS), oxybutynin, and pentosan polysulfate (PPS). A
traditional meta-analysis was also performed.
Results Sixteen trials evaluating 905 patients were included.
Network meta-analysis indicated that BoNTA had the highest
probability of being the best treatment course according to
GRA assessment results (probability 81.7 %). BCG or
BoNTA therapy yielded significant improvement in GRA in-
cidence according to traditional meta-analysis. Patients who
received PPS showed higher urinary frequency results com-
pared with the placebo groups. BCG- and PPS-treated patients
had elevated urinary urgency treatment effects compared with
placebo groups. Bladder capacity restoration results also
showed significant improvements in patients who received
BoNTA compared with placebo-treated individuals.
Conclusions These findings indicate that BoNTA therapy has
the highest probability of being the best therapy according to
GRA, and significantly improves bladder capacity in IC/PBS
patients. BCG treatment also significantly increases the inci-
dence of GRA and improves the symptoms of urinary urgen-
cy. PPS can significantly improve urinary frequency and ur-
gency symptoms in IC/PBS patients.
Keywords Interstitial cystitis . Painful bladder syndrome .
Intravesical treatment . Clinical trials . Meta-analysis
Introduction
Interstitial cystitis/painful bladder syndrome (IC/PBS) is charac-
terized by a constellation of bladder symptoms, including urinary
frequency, urgency, increased nocturia, and bladder and pelvic
pain [1]. The incidence of IC/PBS is variable, with morbidity
rates of 3–4 per 10 million in Japan, 18 per 10million in Europe,
and 60–70 per 10 million in the USA [2]. Epidemiological stud-
ies demonstrated that IC/PBS morbidity is related to race, age,
and gender, further suggesting that the disease most likely affects
30- to 50-year-old women [1, 2]. Furthermore, diagnostic criteria
are variable in different countries [3]. The pathogenesis of IC/
PBS remains unclear; possible pathogenic factors include infec-
tion, autoimmune disease, mast cell infiltration, neurogenic
mechanism, change in mucosal epithelial permeability, and gly-
cosaminoglycan metabolism defect [4, 5].
To date, the main purpose of IC/PBS treatment is to restore
bladder function, prevent recurrence, and improve the quality
of life. There are numerous treatments for IC/PBS, including
diet therapy, behavior adjustment training (BAT), oral medi-
cation, intravesical instillation, and surgical intervention [6].
Electronic supplementary material The online version of this article
(doi:10.1007/s00192-016-3079-4) contains supplementary material,
which is available to authorized users
* Xu Wang
xuwang2003@sina.com
1 Tianjin Institute of Urology, The 2nd Hospital of Tianjin Medical
University, Tianjin Medical University, 23 Pingjiang Road, Hexi
District Tianjin 300211, People’s Republic of China
Int Urogynecol J (2017) 28:515–525
DOI 10.1007/s00192-016-3079-4
Treatment strategies for IC/PBS are given priority based on
empirical evidence, as the mechanism of this ailment remains
unclear. Intravesical perfusion, considered a relatively better
treatment tool, is a technique in which the drug is spread
directly on the inner surface of the bladder to increase its local
concentration and active time while reducing the rate of side
effects. However, randomized controlled trials (RCTs)
assessing intravesical treatment are scarce for every single
drug researched, and comparison of the efficacy of drugs re-
mains controversial.
Current intravesical IC/PBS treatment strategies include
botulinum toxin A (BoNTA), bacillus Calmette–Guerin
(BCG), resiniferatoxin (RTX), lidocaine, chondroitin sulfate
(CS), oxybutynin, and pentosan polysulfate (PPS) [7–11].
Previous studies demonstrated that these interventions can
relieve the clinical symptoms of IC/PBS and restore bladder
function; however, comparative efficacy among these drugs
remains undetermined. Although several systematic reviews
have been previously published, no clear comparisons of treat-
ment effects obtainedwith intravesical medicines are available
[2, 12–15]. The aim of this network meta-analysis was to
assess the comparative efficacy and safety of intravesical med-
icines in IC/PBS patients using both direct and indirect evi-
dence, and to discuss their future use for IC/PBS patients.
Materials and methods
Search strategy and selection criteria
This review was conducted and reported according to the
Preferred Reporting Items for Systematic Reviews and
Meta-Analysis Statement [16] issued in 2009. Any RCTs
evaluating intravesical instillation in IC/PBS patients were
eligible for inclusion, and no restrictions were placed on lan-
guage or publication status (published or in press). The
Medline, EmBase, and Cochrane Library electronic databases
were searched for articles published through October 2015,
with Binterstitial cystitis^ OR Bpainful bladder syndrome^
OR BHunner’s ulcer^ AND Bintravesical^ AND Bclinical
trials^ as the search terms. We also conducted manual
searches of reference lists from all relevant original articles
and reviews to identify additional eligible studies.
The literature search was undertaken independently by two
authors and any inconsistencies were settled by group discus-
sion until a consensus was reached. A study was included if
the following criteria were met:
1. RCT design
2. Assessment of intravesical treatment for IC/PBS patients
3. Outcomes included global response assessment (GRA)
and one of the following: pain, urinary frequency, urinary
urgency, or bladder capacity restoration
Cohort, case–control, and case series studies, in addition to
reviews and editorials, were excluded owing to uncontrolled
confounders.
Data collection and quality assessment
Two reviewers independently extracted all data, with dis-
agreements resolved in consultation with third-party investi-
gators. The following items were extracted from the articles
included: first author name, publication year, country, patient
number, patient gender, age, disease type, interventions, con-
trols, additional treatment regimens, and duration of the
follow-up period. The primary outcome was GRA; secondary
outcomes included pain assessment, urinary frequency, uri-
nary urgency, and bladder capacity. Two reviewers indepen-
dently assessed the quality of the studies included according to
the Cochrane risk of bias tool in the following six domains:
selection, performance, detection, attrition, reporting, and oth-
er bias [17].
Statistical analysis
For traditional meta-analysis, the inverse variancemethodwas
used to pool continuous data; the Mantel–Haenszel method
was utilized for dichotomous data. Results were presented as
standardized mean difference (SMD) with 95 % confidence
intervals (CIs) and odds ratio (OR) with 95 % CIs. In the
network meta-analysis, a random-effects network meta-
analysis was used for mixed multiple treatment comparisons,
fully preserving the within-trial randomized treatment com-
parison of each trial [18].
The I2 index was calculated to evaluate the extent of
variability attributable to statistical heterogeneity between
trials. In the absence of statistical heterogeneity (I2 <
50 %), a fixed-effect model was used in traditional meta-
analysis; otherwise, we used a random-effects model [19,
20]. Consistency within every closed triangle or quadratic
loop was investigated using a loop-specific approach in the
network meta-analysis. During analysis, inconsistency fac-
tors and 95 % CIs were used to determine their compati-
bility with zero [21]. Predictive intervals (PIs) provide an
interval in which future observations will fall [22]. 95 %
PIs were examined to capture the uncertainty and magni-
tude of heterogeneity in the network meta-analysis [23]. To
rank the treatments for an outcome, surface under the cu-
mulative ranking (SUCRA) probabilities was used [24]. A
Bcomparison-adjusted^ funnel plot was used to assess the
presence of small-study effects in the network meta-
analysis [25]. Two-tailed p < 0.05 was considered statisti-
cally significant. Review Manager (version 5.3) and
STATA (version 12.0) were used for data analysis.
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Results
The literature research returned 229 hits after removing dupli-
cations; of these, 16 trials were included in the meta-analysis
(Fig. 1). After a full-text review, the reasons for excluding
reports were non-RCTs [4, 26], other intervention interference
[27, 28], other similar diseases [9, 29, 30], and lack of desired
outcome assessment [31]. The general characteristics of the
studies included are presented in Table 1.
Of the trials included, 4 reported BCG compared with pla-
cebo [32–35], 3 evaluated BoNTA in comparison with place-
bo [8, 36, 37], 2 reported RTX compared with placebo [38,
39], 2 comparatively assessed chondroitin sulfate and placebo
[7, 40], 2 reported PPS compared with placebo [5, 41], 1
evaluated lidocaine compared with placebo [42], 1 reported
oxybutynin compared with placebo [43], and 1 assessed BCG
in comparison with BoNTA [44]. The studies included
assessed 905 patients in all. Female patients accounted for at
least 77 % of all subjects, who were all 18 years or older,
excluding one study that did not mention patient age [35].
One study had a three-arm design, and included 0.05 μM
RTX, 0.1 μM RTX, and placebo control groups [38]; another
study had a four-arm design, and included 0.01 μM RTX,
0.05 μM RTX, 0.1 μM RTX, and placebo control groups
[39]. Five studies identified additional treatments in both
groups, including hydrodistention [8, 37], oral PPS [5, 41],
and antibiotics [45]. The shortest and longest follow-up times
were 29 days and 24 months respectively (Table 1). All the
studies included were RCTs. A summary graph of bias risks
for each study is shown in Fig. 2.
Eligible comparisons for overall treatment response in the
network meta-analysis are presented in Fig. 3, showing pre-
dominantly pairwise comparisons of various drug treatments
for IC/PBS. This figure weights the nodes according to the
number of patients who received each treatment, and the
edges according to the mean control group risk for all com-
parisons versus placebo. The contribution plot for this net-
work meta-analysis is shown in Fig. 4; BCG versus placebo
had the highest contribution for the entire network meta-
analysis (14.8 %). The inconsistency plot was produced with
an assumed loop-specific heterogeneity estimate, and the
exp(IF) (RORs of direct and indirect estimates) shows no sig-
nificant inconsistency in the network meta-analysis (ROR =
1.534; 95 % CI 1.00–16.53; ζ2 = 0.117; p = 0.725; Fig. 5).
The traditional meta-analysis for BCG versus placebo
had similar results with network meta-analysis data (tradi-
tional [OR = 2.58, 95 % CI 1.50–4.42; p = 0.001]; network
[OR = 2.50, 95 % CI 1.47–4.25; p = 0.001]), BoNTA vs
control (traditional [OR = 6.12, 95 % CI 2.11–17.79; p =
0.001]; network [OR = 6.49, 95 % CI 2.53–16.63;
Fig. 1 Flow diagram: preferred
reporting items for systematic
reviews and meta-analysis
(PRISMA) flow diagram
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p < 0.001]). In addition, the current network meta-analysis
showed significant comparisons between BCG vs RTX
(OR = 3.74, 95 % CI 1.53–9.15; p = 0.004) and BoNTA
vs RTX (OR = 9.69, 95 % CI 2.96–31.71; p < 0.001;
Fig. 6). We also ranked the comparative effects of all treat-
ments for IC/PBS with SUCRA probabilities (%).
Interestingly, BoNTA had the most likely chance of being
the best therapy (probability of 81.7 %); the cumulative
ranking plots based on our estimates are shown in Fig. 7.
The comparison-adjusted funnel plot for assessing publi-
cation bias of small-study effects within a network of in-
terventions is depicted in Fig. 8.
In the traditional meta-analysis, GRA results indicated that
BCG had a significantly better treatment effect than placebo
Fig. 2 Methodological quality of trials included in the meta-analysis: risk of bias graph and summary
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control (OR = 2.58, 95 % CI 1.50–4.42; p = 0.001); BoNTA
treatment also had significantly superior effect to placebo con-
trol (OR = 6.12, 95 % CI 2.11-17.79; p = 0.001), while other
results showed no significant differences (Figure S1). Pain
data revealed that BoNTA had a significant decrease in pain
compared with BCG (SMD = 1.39, 95 % CI 0.61–2.61;
Fig. 3 Evidence network for
medicines in the meta-analysis:
networks of eligible comparisons
for overall treatment response
showed predominantly pairwise
comparisons of different drug
treatments in interstitial cystitis/
painful bladder syndrome (IC/
PBS). The figure weights the
nodes according to the number of
patients who have received each
treatment and the edges according
to the mean control group risk for
all comparisons versus placebo.
PLB placebo, OXY oxybutynin,
LID lidocaine, CS chondroitin
sulfate, BoNTA botulinum toxin
A, BCG bacillus Calmette–
Guerin, RTX resiniferatoxin, PPS
pentosan polysulfate
Fig. 4 Forest plot from network meta-analysis showing a summary of the treatment effects in IC/PBS
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p < 0.001). However, these results are of very low reliability as
they were reported by only one study (Figure S2).
Urinary frequency data showed that the treatment effect of
PPS was significantly lower than that of placebo control
(SMD= 1.91, 95 % CI 1.17–2.66; p < 0.001); BoNTA treat-
ment was significantly superior to BCG intervention (SMD=
3.49; 95 % CI 2.37-4.62; p < 0.001), whereas no other
significant comparisons were possible (Figure S3). Urinary
urgency data showed that BCG treatment was significantly
superior to that of placebo control (SMD= −0.59, 95 % CI
−1.09–0.08; p = 0.024); PPS treatment was also superior to
placebo control (SMD = −0.78, 95 % CI −1.42–0.14; p =
0.016). Additionally, BoNTA had a better treatment effect
compared with BCG intervention (SMD = 2.40, 95 % CI
Fig. 5 Cumulative ranking plots based on the estimations from surface under the cumulative ranking (SUCRA) probabilities
Fig. 6 Contribution plot for this network meta-analysis. Contributions matrix: percentage contribution of each direct or indirect estimate to the network
meta-analysis
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1.48–3.32; p < 0.001; Figure S4). Bladder capacity restora-
tion results showed that the BoNTA group showed signif-
icant improvement compared with placebo-treated control
patients (SMD = 0.53, 95 % CI 0.14–0.92; p = 0.007;
Figure S5).
Discussion
This updated network meta-analysis included 16 RCTs eval-
uating intravesical interventions in adult patients with IC/PBS.
The findings of the current meta-analysis suggested that:
Fig. 7 Inconsistency plot to assume loop-specific heterogeneity
Fig. 8 Comparison-adjusted
funnel plot for assessing small-
study effects within a network of
interventions
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1. BoNTA has the highest probability of being the best ther-
apy for improving GRA assessment and significantly
ameliorates bladder capacity in IC/PBS patients
2. BCG treatment significantly improves GRA results and
symptoms of urinary urgency
3. PPS significantly improves urinary frequency and urgen-
cy symptoms in IC/PBS patients
In this research, network meta-analysis was used to assess the
therapeutic effects of different medicines in IC/PBS patients
for the first time.
In a previous meta-analysis, Dawson and Jamison consid-
ered BCG and oxybutynin to be well-tolerated and promising
for the intravesical treatment of IC/PBS, whereas RTX, di-
methyl sulfoxide (DMSO), and PPS showed no evident ef-
fects for most outcomes [2]. Tirumuru et al. suggested that
BoNTA might show a trend toward short-term benefit on
urodynamic parameters based on RCTs [6]. Giannantoni
et al. proposed a comprehensive IC/PBS treatment strategy,
such as oral medication, intravesical instillations, and com-
bined treatment, but the results obtained had high heterogene-
ity, with uncertain conclusions [14]. Matsuoka et al. suggested
that BCG therapy could improve most symptoms, but not 24-
h urinary frequency [12]. Moreover, Guo et al. considered that
RTX could significantly reduce bladder pain, but not improve
urinary frequency [13]. According to Dawson and Jamison,
DMSO instillations show a non-increase in cystometric capac-
ity, with limited evidence [2]. A recent systematic review
based on RCTs still did not clearly indicate the best approach
for IC/PBS treatment [43]. Overall, the greatest obstacle in
improving IC/PBS treatment stems from the various interven-
tions and diverse outcome assessments, which make results
inconsistent. Therefore, an update of these systematic reviews
is needed to define the comparison among intravesical
treatments.
In this study, the intervention method of the RCTs included
was restricted to intravesical instillation treatment because it is
widely used as the first line of treatment in IC/PBS patients
[44]. We excluded non-RCTs with a high design bias, to in-
crease the reliability of our research, because the treatment and
outcome records of IC/PBS are subject to high subjectivity,
especially pain and urgency records.We also updated the trials
included to incorporate the most recently published review
[8], and comparatively analyzed various intravesical treat-
ments by network meta-analysis. However, Peeker et al.’s
RCT comparing DMSO and BCG was finally excluded from
both network and traditional meta-analyses in this study.
Indeed, inclusion criteria in the network meta-analysis mainly
focused on overall response, whereas outcome data in the
above study were unavailable. Meanwhile, in the traditional
meta-analysis, only one high-quality RCT was available, and
it could not be taken into account. Moreover, DMSO through
intravesical instillation was approved by the United States
Food and Drug Administration (FDA) for use in the treatment
of IC [46], indicating that there is less controversy over this
compound.
This review did not assess oral medications for IC/PBS
treatment, mainly because oral medicines include analgesics,
hormones, and antidepressants. These drugs can alleviate
symptoms; for example, oral PPS showed a relatively positive
response in treating pain and urgency symptoms [14].
However, oral medications have limited efficiency, and are
usually associated with high rates of side effects, especially
oral antidepressants and hormones [13]. Surgery is another
option in the treatment of IC/PBS, but is generally utilized
when more conservative treatments are not effective. The em-
pirical medicines used in intravesical treatment include local
anesthetics (e.g., lidocaine), bladder glycosaminoglycan
(GAG) layer repair agent (e.g., heparin, sodium hyaluronate,
and CS), anti-inflammatory agents and free radical scavengers
(e.g., DMSO), substance P agonists (e.g., RTX), and acetyl-
choline release inhibitors (e.g., BoNTA). Despite the variety
of medicines for IC/PBS treatment, no widely accepted effec-
tive treatment is available. In the current network meta-anal-
ysis, BoNTAwas relatively the best intravesical medicine for
IC/PBS with regard to overall treatment response. PPS ranked
second highest in the probability of being the best therapy
(8.7 %) in this network meta-analysis and lidocaine had the
third highest possibility (6.8 %).
In the above traditional meta-analysis, BoNTA, which is
extracted from botulinum toxin, significantly improved the
GRA of IC/PBS patients compared with placebo. Because of
its high molecular weight, BoNTA is limited in the ability to
cross the urothelium and reach the suburothelial nervous plex-
us and bladder smooth muscles; therefore, intravesical instil-
lation has not been applied for routine delivery of BoNTA
[47]. According to Gao and Liao [48], combination therapy
with intravesical BoNTA injection and hydrodistention plus
Cystistat instillation is effective for treating IC/PBS.
Additionally, significant improvements in VAS, interstitial
cystitis symptom indexes, and frequency were previously re-
ported [49]. Therefore, the intravesical injection of BoNTA is
the most effective known treatment for IC/PBS. Bladder ca-
pacity was also significantly improved after BoNTA treat-
ment. However, BoNTA showed no treatment advantages
with regard to pain, urinary frequency, and urgency results.
In one trial, BoNTA showed a significant treatment effect on
pain, urinary frequency, and urgency comparedwith BCG, but
these findings require further research for confirmation [45].
The mechanism of BCG in IC/PBS treatment remains unclear
though it may be related to local immune system impairment
[28]. As shown above, BCG significantly improved GRA and
urinary urgency in IC/PBS patients. Other intravesical instil-
lation medicines showed no improvements in GRA. PPS, a
heparin-like sulfated polysaccharide, was also approved by
the FDA as an oral medicine in IC/PBS treatment [22].
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However, PPS by intravesical instillation only showed a ther-
apeutic effect on urinary urgency in this study.
The limitations of this study should be mentioned. First, we
had no specific data regarding individuals for any of the trials
included; thus, statistical analysis could only be performed for
each study. Second, the number of RCTs using a single med-
icine was limited, which may reduce the reliability of the
meta-analysis. Third, heterogeneity in pain outcome was
found among the studies included, which may be attributed
to the non-standardization of pain assessment. Finally, we
were not able to use subgroup analysis and meta-regression
to reduce the observed heterogeneity because of the limited
number of RCTs assessing single medicines. Therefore, uni-
fying outcome standards is very important in further research.
In conclusion, BoNTA has the highest probability of being
the best therapy for IC/PBS according GRA assessment re-
sults, and can significantly improve bladder capacity recovery.
BCG treatment can also significantly improve GRA incidence
and urinary urgency, and PPS can significantly improve uri-
nary frequency and urgency symptoms in IC/PBS patients.
Further research would benefit not only from more well-
designed RCTs, but also from studies focusing on the patho-
genesis and therapeutic mechanisms of IC/PBS to further im-
prove understanding of the disease and its treatments.
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